ArticlePloS one2023

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.

Jingyang Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.